Decreased blood-brain barrier expression of P-glycoprotein in Alzheimer's disease: Impact on pathogenesis and brain access of therapeutic agents

Therapeutic Delivery

Volumn 2, Issue 7, 2011, Pages 841-844

  Nicolazzo, Joseph A ^a   Banks, William A ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; blood brain barrier; CNS; efflux transporter; P glycoprotein; amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; DIGOXIN; GLYCOPROTEIN P; LOPERAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MORPHINE; PHENYTOIN; QUINIDINE; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; VERAPAMIL;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL MEMBRANE TRANSPORT; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; HUMAN; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW;

EID: 79961198571     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.65     Document Type: Review

References (29)

1. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2(1), 86-98 (2005). (Pubitemid 40128029)
2. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89(11), 1371-1388 (2000).
3. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34(1), 207-217 (1967).
4. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug. Deliv. Rev. 36(2-3), 179-194 (1999).
5. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2), 178-201 (2008).
6. Ronaldson PT, Davis TP. Targeting molecular mechanisms of blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery Ther. Deliv. DOI: 10.4155/TDE.11.67 (2011) (In press).
7. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81(2), 741-766 (2001).
8. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28(4), 202-208 (2005).
9. Deane R, Wu Z, Sagare A et al. LRP/amyloid b-peptide interaction mediates differential brain efflux of Ab isoforms. Neuron 43(3), 333-344 (2004). (Pubitemid 39061126)
10. Lam FC, Liu R, Lu P et al. b-amyloid efflux mediated by p-glycoprotein. J. Neurochem. 76(4), 1121-1128 (2001).
11. Kuhnke D, Jedlitschky G, Grube M et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-b peptides: implications for the mechanisms of Ab clearance at the blood-brain barrier. Brain Pathol. 17(4), 347-353 (2007). (Pubitemid 47537591)
12. Cirrito JR, Deane R, Fagan AM et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-b deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115(11), 3285-3290 (2005). (Pubitemid 41567593)
13. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain Ab in a mouse model of Alzheimer's disease. Mol. Pharmacol. 77(5), 715-723 (2010).
14. Tai LM, Loughlin AJ, Male DK, Romero IA. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-b. J. Cereb. Blood Flow Metab. 29(6), 1079-1083 (2009).
15. Candela P, Gosselet F, Saint-Pol J et al. Apical-to-basolateral transport of amyloid-b peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J. Alzheimer Dis. 22(3), 849-859 (2010).
16. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-b peptide (1-40) across the rat blood-brain barrier. Neurosci. Res. 56(3), 246-242 (2006).
17. Yamada K, Hashimoto T, Yabuki C et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid b peptides in an in vitro model of the blood-brain barrier cells. J. Biol. Chem. 283(50), 34554-34562 (2008).
18. Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-b peptide in a blood-brain barrier in vitro model. Neurobiol. Dis. 30(1), 94-102 (2008).
19. Vogelgesang S, Cascorbi I, Schroeder E et al. Deposition of Alzheimer's b-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12(7), 535-541 (2002). (Pubitemid 35177083)
20. Vogelgesang S, Warzok RW, Cascorbi I et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 1(2), 121-125 (2004).
21. Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA. ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Res. 1358, 228-238 (2010).
22. Jeynes B, Provias J. An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis. Neurosci. Lett. 487(3), 389-393 (2011).
23. Rizzi M, Caccia S, Guiso G et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J. Neurosci. 22(14), 5833-5839 (2002).
24. Seelbach MJ, Brooks TA, Egleton RD, Davis TP. Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J. Neurochem. 102(5), 1677-1690 (2007). (Pubitemid 47256196)
25. Bartels AL, Kortekaas R, Bart J et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging 30(11), 1818-1824 (2009).
26. Bartels AL, Willemsen AT, Kortekaas R et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural. Transm. 115(7), 1001-1009 (2008).
27. Salkeni MA, Lynch JL, Otamis-Price T, Banks WA. Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin-and nitric oxide-independent pathways. J. Neuroimmune Pharmacol. 4(2), 276-282 (2009).
28. Lubberink M, Van Assema D, Hendrikse NH, Schuit R, Lammertsma A, Van Berckel B. Decreased P-glycoprotein function at the blood-brain barrier in patients with Alzheimer's disease as shown by (R)-[11C] verapamil and PET. J. Nucl. Med. 51(Suppl. 2), 443 (2010).
29. Nicolazzo JA, Mehta DC. Transport of drugs across the blood-brain barrier in Alzheimer's disease. Ther. Deliv. 1(4), 595-611 (2010).